Pancreatic Tumor
Conditions
Keywords
pancreatic tumor, neoantigen, vaccine
Brief summary
This clinical trial is to evaluate the safety and impact on prognosis of personalized neoantigen peptide-based vaccines, which are based on next-generation sequencing and major histocompatibility complex affinity prediction algorithm, in patients with pancreatic ductal adenocarcinoma. The hypothesis of this study is that personalized neoantigen vaccines will be safe and can systemically elicit measurable neoantigen-specific immunologic responses in patients. Participants will receive complete macroscopic resection of primary tumor, standard adjuvant chemotherapy and subsequently personalized neoantigen vaccines.
Detailed description
This is a single-center, open-label Phase Ib clinical trial. In this trial, adult subjects with pancreatic ductal adenocarcinoma who have completed resection of the primary tumor and who have not undergone preoperative chemotherapy will be enrolled in the study. Eligible enrolled patients all will undergo tumor resection and all receive adjuvant chemotherapy prior to preparation of the personalized neoantigen vaccine. After the chemotherapy finish, subsequently patients will receive a priming immunization with five doses of the personalized neoantigen vaccine over one month and a boosting immunization with two doses three months later. This clinical trial will examine the safety and effect of the personalized neoantigen vaccine when given at several different time points and will examine the participant's peripheral blood cells for signs that the vaccine induces immunologic responses. Finally we will establish the typical flow to assess efficiency and safety of vaccines according to the different reactivity of patients, as a result, to explore the most suitable practical approaches for applying personalized pancreatic tumor vaccines.
Interventions
BIOLOGICALPersonalized neoantigen vaccine
Patients will have complete resection of primary tumor without preoperative chemotherapy. Patients will receive postoperative chemotherapy and subsequently personalized vaccines on days 1, 4, 8, 15, 22 (priming phase) and weeks 12, 20 (boosting phase). Personalized vaccines will consist of several distinct peptides (the dose is 0.3 mg/peptide) that are grouped into 2-4 pools and 0.5 mg of poly-ICLC as the adjuvant for each pool. Injection sites will be 2-4 separate sites of the subject's thighs.
Sponsors
Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologic diagnosis of pancreatic ductal adenocarcinoma 2. Aged ≥20 and ≤75 3. Male or not pregnant women 4. Undergone radical resection (R0 status of resection margins \[no cancer cells within 1 mm of all resection margins\]) 5. No serious underlying disease, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 6. No chemotherapy or radiotherapy before resection surgery 7. No significant cardiac, lung, liver, kidney, and bone marrow insufficiency 8. No HIV or syphilis infection 9. Signing informed consent
Exclusion criteria
1. Poor postoperative situation 2. Obvious organ dysfunction 3. Radiographically confirmed recurrence or metastasis within 180 days after the surgery 4. Unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmias, Myocardial infarction in the past 6 months, and prolonged QT interval (\> 450ms) 5. Previous malignant tumors other than pancreatic cancer 6. Cannot be follow up 7. Participating in other clinical trials 8. Without chemotherapy after resection surgery Exit criteria: 1. Missed within one month after surgery or not follow-up as required 2. Patient's own willingness to withdraw 3. Concurrent disease or severe adverse events 4. Protocol violations 5. Administrative reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and grades of adverse events as assessed by CTCAE v5.0 | From the first dose of vaccination through 2 years after the surgery | Safety will be assessed by the rate of grade 3 or worse adverse events (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence-free survival | From the date of resection surgery until the date of the first confirmed tumor recurrence or date of death from any cause or date of study completion, whichever came first, assessed up to 6 years. | The time between resection surgery and the tumor recurrence (radiological assessment of disease status according to RECIST1.1 criteria). |
| Overall survival | From the date of resection surgery until the date of death from any cause or date of study completion, whichever came first, assessed up to 6 years. | The time between resection surgery and the death (any cause). |
| Serum CA19-9 or CA72-4 levels | From the date of resection surgery until the date of last documented examination of CA19-9 and CA72-4 or date of study completion, whichever came first, assessed up to 6 years. | The rate of patients without the abnormal elevation of the serum CA19-9 (Cancer Antigen 19-9) or CA72-4 (Cancer Antigen 72-4) levels will be assessed during the vaccination and post-treatment follow-up. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Levels of interferon-γ responses in peripheral blood mononuclear cells | From the date of first dose of vaccination through 264 days after the first dose of vaccination. | Ex vivo Enzyme-linked Immunospot assay will be performed to detect the levels of interferon-γ responses of the neoantigen peptides in the stimulation of peripheral blood mononuclear cells. Data will be presented as the ratio of the adjusted spot-forming count of peptide stimulation to the corresponding non-stimulated negative control. |
| Percentages of immune cell populations in peripheral blood during the vaccination | From the date of first dose of vaccination through 264 days after the first dose of vaccination. | The percentages of immune cells including natural killer (NK) cells, T cells, B cells, macrophages, monocytes, dendritic cells and granulocytes as well as their subtypes will be detected in the peripheral blood of patients during the vaccination. The percentages of specific T-cell or B-cell clonotypes will also be detected during the vaccination. Ten-color flow cytometry and single-cell transcriptome sequencing will be performed to evaluate the percentage of the immune cell populations. Single-cell T/B-cell repertoire sequencings will be performed to profile the expansion of T-cell or B-cell clonotypes. |
Countries
China
Contacts
Primary ContactShiwei Guo, Doctor
Backup ContactSuizhi Gao, Master
Outcome results
None listed